Lilly fails to meet expectations of Wall Street for one quarter due to production issues and distribution issues and you announce that the run-up is over. Whatever you do, don't give up that day job to become an analyst.
Novo Nordisk finally got their act together and once the fda removes their weight-loss drugs from the shortage list, patent law will be enforced, ending compounding and cheap alternatives.
Maybe it never occurred you but if Eli Lilly is having problems with distribution and Manufacturing enough volume, the same problems will present themselves if and when the competition arrives.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
